Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85